To deliver actionable results that can contribute to a clinically meaningful difference in cancer treatment.
The development of state-of-the-art cancer diagnostics and prognostics.
Our strength is in our people. We believe hard working, dedicated people make a significant difference.
To meet and exceed expectations. Never stand still or accept second best.
From Discovery to Market
About Pacific Edge
Pacific Edge encompasses a diverse range of expertise covering all stages in the product life cycle. Our capabilities include cancer genetics, molecular oncology, bioinformatics, clinical research, technology commercialisation, marketing and sales.Read More
Shareholder reports, key dates and services
Pacific Edge is listed on the NZX Main Board and provides an opportunity to invest into the fast growing cancer diagnostic market. Here you will find all the information you need to know about being a shareholder of Pacific Edge Limited.Read More
Diagnostic and Prognostic Technology
Products by Pacific Edge
Pacific Edge has its innovative bladder cancer diagnostic technology, Cxbladder in the marketplace. We are building a complete suite of Cxbladder products to meet a variety of clinical needs.Read More
News & Events
Latest news updates, announcements and calendar of events.
Pacific Edge Full Year Results to be Announced 29 May 2019
Pacific Edge Limited (NZX:PEB) advises that it intends to announce its full year result for the financial year ended 31 March 2019 on Wednesday 29 May 2019, prior to 10am NZST. [read more]Read More
Sign up to receive email notification of news and announcements from Pacific Edge.Subscribe Here
An online community where people affected by bladder cancer can connect with one another, share experiences and support each other in a safe, secure environment.Read More
Pacific Edge understands the critical role that access to information, tools and the mutual support of others, plays in proactive health management. We are proud to be foundation sponsors of bladdercancer.me, an online community initiative from our partner, Melon Health.